By Rukayatu Musah
A high-level Ghanaian delegation, led by the Board Chairman of Ghana’s Food and Drugs Authority (FDA), Hudu Mogtari, has paid a working visit to the state-of-the-art facilities of Virupaksha Organics in Hyderabad, India.
The delegation expressed admiration for the company’s impressive achievements and global standing. With an annual revenue of USD 80 million, Virupaksha Organics operates cutting-edge manufacturing plants and advanced research and development centers.
The company has earned approvals from major international regulatory agencies, including the U.S. FDA, ANVISA (Brazil), COFEPRIS (Mexico), KFDA (Korea), TGA (Australia), and PMDA (Japan) — underscoring its commitment to meeting the highest global standards.
Virupaksha Organics has also invested heavily in innovative chemical technologies, particularly flow reaction systems, designed to make pharmaceutical processes safer and more environmentally sustainable.
Mr. Mogtari praised the company’s commitment to technological excellence and safety, describing Virupaksha Organics’ operations as “a much safer option comparatively.”
He highlighted Ghana’s strategic position, conducive business environment, and robust regulatory framework as key factors that make the country the most attractive investment destination in sub-Saharan Africa.
“Ghana is currently the most preferred investment destination,” Mr. Mogtari emphasized, citing the nation’s maturity level 3 regulatory framework as recognized by the World Health Organization (WHO).
He urged Virupaksha Organics to fast-track the establishment of its Ghana branch, leveraging the country’s growing pharmaceutical market and its gateway position to the rest of Africa.
Virupaksha Organics, a leading Indian pharmaceutical company, has expressed strong intent to make a transformative impact on Ghana’s and Africa’s healthcare sectors.
With its solid financial base, modern infrastructure, and technical expertise, the company is confident in its ability to emerge as a dominant player in the region’s pharmaceutical industry.
Sustainability is a central pillar of Virupaksha Organics’ growth strategy. The company aims to transition to 50% renewable energy by 2030 and achieve carbon neutrality by the same year — aligning its vision with Ghana’s broader national goals of sustainable industrialization and improved healthcare delivery.
Virupaksha Organics’ expansion plans promise not only to enhance access to quality medicines in Ghana and Africa but also to strengthen economic ties between India and Ghana, marking a new chapter in South-South cooperation for the pharmaceutical sector.
